Is CDMO undervalued or overvalued?
As of 2025-04-18, the Intrinsic Value of Avid Bioservices Inc (CDMO) is 3.51 USD. This CDMO valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 12.49 USD, the upside of Avid Bioservices Inc is -71.90%. This means that CDMO is overvalued by 71.90%.
The range of the Intrinsic Value is 2.23 - 5.43 USD
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (18.56) - (5.64) | (7.80) | -162.5% |
| DCF (Growth 10y) | (3.38) - (4.92) | (3.66) | -129.3% |
| DCF (EBITDA 5y) | 2.23 - 5.43 | 3.51 | -71.9% |
| DCF (EBITDA 10y) | 4.11 - 10.20 | 6.50 | -48.0% |
| Fair Value | -11.85 - -11.85 | -11.85 | -194.90% |
| P/E | (39.59) - (72.30) | (59.09) | -573.1% |
| EV/EBITDA | (3.61) - 11.33 | 1.40 | -88.8% |
| EPV | (7.13) - (9.41) | (8.27) | -166.2% |
| DDM - Stable | (24.68) - (115.31) | (70.00) | -660.4% |
| DDM - Multi | (0.40) - (1.46) | (0.63) | -105.0% |
| Market Cap (mil) | 801.11 |
| Beta | 1.95 |
| Outstanding shares (mil) | 64.14 |
| Enterprise Value (mil) | 929.68 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.29% |
| Cost of Debt | 5.50% |
| WACC | 7.57% |